685 related articles for article (PubMed ID: 25482745)
1. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.
Cooley L; Dendle C; Wolf J; Teh BW; Chen SC; Boutlis C; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1350-63. PubMed ID: 25482745
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
4. Question 1: Co-trimoxazole dosing dilemma: what is the right dose?
Boast A; Osowicki J; Cole T; Curtis N; Gwee A
Arch Dis Child; 2015 Nov; 100(11):1089-93. PubMed ID: 26408788
[No Abstract] [Full Text] [Related]
5. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation.
Brakemeier S; Pfau A; Zukunft B; Budde K; Nickel P
Pharmacol Res; 2018 Aug; 134():61-67. PubMed ID: 29890253
[TBL] [Abstract][Full Text] [Related]
6. Should patients with malignancy receive chemoprophylaxis against Pneumocystis jirovecii pneumonia?
Barbounis V
Nat Clin Pract Oncol; 2005 Oct; 2(10):490-1. PubMed ID: 16205763
[No Abstract] [Full Text] [Related]
7. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Evaluation of Risk Factors for Pneumocystis jirovecii Pneumonia in Adult Solid Organ Transplant Recipients: A Systematic Review and Meta-analysis.
Permpalung N; Kittipibul V; Mekraksakit P; Rattanawong P; Nematollahi S; Zhang SX; Steinke SM
Transplantation; 2021 Oct; 105(10):2291-2306. PubMed ID: 33323766
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
10. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
11. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis.
Anand S; Samaniego M; Kaul DR
Transpl Infect Dis; 2011 Dec; 13(6):570-4. PubMed ID: 22093215
[TBL] [Abstract][Full Text] [Related]
13. [Pneumocystis pneumonia in patients with immunosuppression other than HIV infection].
Adler D; Chenivesse C; Similowski T; Soccal PM
Rev Med Suisse; 2008 Nov; 4(180):2525-6, 2528-30. PubMed ID: 19127897
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.
Proudfoot R; Phillips B; Wilne S
J Pediatr Hematol Oncol; 2017 Apr; 39(3):194-202. PubMed ID: 28267082
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sulfamethoxazole-Trimethoprim on Airway Colonization with Pneumocystis jirovecii.
Kushima H; Ishii H; Tokimatsu I; Umeki K; Sato T; Kadota J
Jpn J Infect Dis; 2016 May; 69(3):252-5. PubMed ID: 26255727
[TBL] [Abstract][Full Text] [Related]
17. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
Quinn M; Fannin JT; Sciasci J; Bragg A; Campbell PK; Carias D; Crews KR; Gregornik D; Jeha S; Maron G; Pauley JL; Swanson HD; Wolf J; Greene W
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866879
[No Abstract] [Full Text] [Related]
18. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.
Basiaga ML; Ross ME; Gerber JS; Ogdie A
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):283-289. PubMed ID: 28992298
[TBL] [Abstract][Full Text] [Related]
20. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
